CA3041959A1 - New biomarkers of human skin aging - Google Patents

New biomarkers of human skin aging Download PDF

Info

Publication number
CA3041959A1
CA3041959A1 CA3041959A CA3041959A CA3041959A1 CA 3041959 A1 CA3041959 A1 CA 3041959A1 CA 3041959 A CA3041959 A CA 3041959A CA 3041959 A CA3041959 A CA 3041959A CA 3041959 A1 CA3041959 A1 CA 3041959A1
Authority
CA
Canada
Prior art keywords
protein
skin
expression level
tubb3
hmga2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3041959A
Other languages
English (en)
French (fr)
Inventor
Sandrine BOURGOIN-VOILLARD
Sylvia Marie-Louise LEHMANN
Walid RACHIDI
Michel Seve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Grenoble Alpes
Original Assignee
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Grenoble Alpes filed Critical Universite Grenoble Alpes
Publication of CA3041959A1 publication Critical patent/CA3041959A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
CA3041959A 2016-11-25 2017-11-24 New biomarkers of human skin aging Pending CA3041959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306561 2016-11-25
EP16306561.8 2016-11-25
PCT/EP2017/080414 WO2018096117A1 (en) 2016-11-25 2017-11-24 New biomarkers of human skin aging

Publications (1)

Publication Number Publication Date
CA3041959A1 true CA3041959A1 (en) 2018-05-31

Family

ID=57517827

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3041959A Pending CA3041959A1 (en) 2016-11-25 2017-11-24 New biomarkers of human skin aging

Country Status (7)

Country Link
US (1) US20210109111A1 (OSRAM)
EP (1) EP3545301A1 (OSRAM)
JP (1) JP7115756B2 (OSRAM)
CN (1) CN110268263B (OSRAM)
CA (1) CA3041959A1 (OSRAM)
RU (1) RU2019116069A (OSRAM)
WO (1) WO2018096117A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020024715A2 (pt) * 2018-06-04 2021-03-23 Avon Products. Inc. biomarcadores proteicos para identificar e tratar o envelhecimento da pele e afecções cutâneas
JP7633003B2 (ja) * 2019-11-29 2025-02-19 ポーラ化成工業株式会社 抗老化成分のスクリーニング方法
WO2023090901A1 (ko) * 2021-11-18 2023-05-25 의료법인 성광의료재단 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법
WO2023133240A1 (en) * 2022-01-07 2023-07-13 Revela, Inc. Compositions, formulations, and methods for skin treatment
JP2023130972A (ja) * 2022-03-08 2023-09-21 株式会社 資生堂 黄ぐすみ抑制方法、黄ぐすみ抑制剤のスクリーニング方法、及び黄ぐすみ感受性の評価方法
CN121208353A (zh) * 2025-08-22 2025-12-26 北京大学第一医院(北京大学第一临床医学院) 一种辅助诊断pcos自发性早产的蛋白质生物标志物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068804A2 (en) * 2000-03-10 2001-09-20 Lifespan Biosciences, Inc. Nucleic acid sequences associated with aging, particularly skin aging
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2004083398A2 (en) * 2003-03-17 2004-09-30 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Therapeutic uses of hmgn1 and hmgn2
US7972788B2 (en) * 2005-08-23 2011-07-05 Fancl Corporation Skin aging marker and technique for use thereof
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
KR100999261B1 (ko) * 2007-10-09 2010-12-07 (주)아모레퍼시픽 여성호르몬 결핍으로 초래되는 여성 피부의 노화 억제제 스크리닝 방법
FR2925313A1 (fr) * 2007-12-19 2009-06-26 Oreal Utilisation cosmetique de proteines de type plakoglobine
US20120034613A1 (en) * 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
EP2704728A4 (en) * 2011-05-03 2015-04-22 Dermachip Inc EXPRESSION SIGNATURES OF AGENTS ASSOCIATED WITH SKIN AGING AND GEN NETWORKS
MX2015012298A (es) * 2013-03-15 2015-12-16 Procter & Gamble Un metodo no invasivo para medir peptidos antimicrobianos de la piel como una medicion objetica de proteccion natural de los microbios.

Also Published As

Publication number Publication date
CN110268263B (zh) 2022-07-19
RU2019116069A (ru) 2020-12-25
EP3545301A1 (en) 2019-10-02
WO2018096117A1 (en) 2018-05-31
JP2020502498A (ja) 2020-01-23
US20210109111A1 (en) 2021-04-15
JP7115756B2 (ja) 2022-08-09
CN110268263A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
US20210109111A1 (en) New biomarkers of human skin aging
Kuppusamy et al. Proteins are potent biomarkers to detect colon cancer progression
US8455208B2 (en) Biomarkers for follicular thyroid carcinoma and methods of use
Yang et al. Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis
Chanthammachat et al. Comparative proteomic analysis of oral squamous cell carcinoma and adjacent non-tumour tissue from Thailand
Jiang et al. Quantitative proteomic analysis reveals that proteins required for fatty acid metabolism may serve as diagnostic markers for gastric cancer
WO2007023808A1 (ja) 皮膚老化マーカーとその利用技術
Lehmann et al. Tubulin Beta‐3 Chain as a New Candidate Protein Biomarker of Human Skin Aging: A Preliminary Study
Li et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer
Li et al. Membrane proteomic analysis comparing squamous cell lung cancer tissue and tumour-adjacent normal tissue
Krapfenbauer et al. Identification of tumour-related proteins as potential screening markers by proteome analysis—protein profiles of human saliva as a predictive and prognostic tool
Qi et al. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma
Bhat et al. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan
Pierredon et al. Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight
Boraldi et al. Hypoxia influences the cellular cross-talk of human dermal fibroblasts. A proteomic approach
Ma et al. Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma
Succoio et al. Proteomic analysis reveals novel common genes modulated in both replicative and stress-induced senescence
Kwon et al. Unveiling the role of transgelin as a prognostic and therapeutic target in kidney fibrosis via a proteomic approach
Zhou et al. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma
Ucal et al. Proteomic analysis reveals differential protein expression in variants of papillary thyroid carcinoma
Shiiba et al. Down-regulated expression of family with sequence similarity 3, member B (FAM3B), in oral squamous cell carcinoma
CN111381042B (zh) 肝细胞癌中大血管侵犯的预测方法、试剂盒及其应用
EP2742351A1 (en) Materials and methods for determining sensitivity potential of compounds
EP2581745B1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
Oumeraci et al. Bronchoalveolar lavage fluid of lung cancer patients: mapping the uncharted waters using proteomics technology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220728